AcquisitionOther
Yarrow Bioscience, Inc. acquired target
Public M&A record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Yarrow Bioscience, Inc. -> target · $200 million
"Yarrow is emerging with multiple value drivers anchored by YB-101, our potentially first-in-class anti-TSHR antibody, and the opportunity to address two significant market opportunities in GD and TED with a single product candidate," said Rebecca V.
Open source record (SEC) ↗